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Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis
in the Hospital Setting Across Asian Countries
Julia A. Bielicki, MD; Mike Sharland, MD; Paul T. Heath, FRCPCH; A. SarahWalker, PhD; Ramesh Agarwal, MD; Paul Turner, PhD; David A. Cromwell, PhD
Abstract
IMPORTANCE High levels of antimicrobial resistance in neonatal bloodstream isolates are being
reported globally, including in Asia. Local hospital antibiogram data may include too few isolates to
meaningfully examine the expected coverage of antibiotic regimens.
OBJECTIVE To assess the coverage offered by 3 antibiotic regimens for empirical treatment of
neonatal sepsis in Asian countries.
DESIGN, SETTING, ANDPARTICIPANTS A decision analytical model was used to estimate coverage
of 3 prespecified antibiotic regimens according to a weighted-incidence syndromic combination
antibiogram. Relevant data to parameterize themodels were identified from a systematic search of
OvidMEDLINE and Embase. Data fromAsian countries published from 2014 onwardwere of interest.
Only data on blood culture isolates from neonates with sepsis, bloodstream infection, or bacteremia
reported from the relevant setting were included. Data analysis was performed from April 2019 to
July 2019.
EXPOSURES The prespecified regimens of interest were aminopenicillin-gentamicin, third-
generation cephalosporins (cefotaxime or ceftriaxone), and meropenem. The relative incidence of
different bacteria and their antimicrobial susceptibility to antibiotics relevant for determining
expected concordance with these regimens were extracted.
MAINOUTCOMES ANDMEASURES Coverage was calculated on the basis of a decision-treemodel
incorporating relative bacterial incidence and antimicrobial susceptibility of relevant isolates. Data
on 7 bacteria most commonly reported in the included studies were used for estimating coverage,
which was reported at the country level.
RESULTS Data from 48 studies reporting on 10 countries and 8376 isolates were used. Individual
countries reported 51 (Vietnam) to 6284 (India) isolates. Coverage varied considerably between
countries. Meropenemwas generally estimated to provide the highest coverage, ranging from
64.0% (95% credible interval [CrI], 62.6%-65.4%) in India to 90.6% (95% CrI, 86.2%-94.4%) in
Cambodia, followed by aminopenicillin-gentamicin (from 35.9% [95% CrI, 27.7%-44.0%] in
Indonesia to 81.0% [95%CrI, 71.1%-89.7%] in Laos) and cefotaxime or ceftriaxone (from 17.9% [95%
CrI, 11.7%-24.7%] in Indonesia to 75.0% [95% CrI, 64.8%-84.1%] in Laos). Aminopenicillin-
gentamicin coverage was lower than that of meropenem in all countries except Laos (81.0%; 95%
CrI, 71.1%-89.7%) and Nepal (74.3%; 95% CrI, 70.3%-78.2%), where 95% CrIs for aminopenicillin-
gentamicin andmeropenemwere overlapping. Third-generation cephalosporin coverage was lowest
of the 3 regimens in all countries. The coverage difference between aminopenicillin-gentamicin and
meropenem for countries with nonoverlapping 95% CrIs ranged from −15.9% in China to −52.9%
in Indonesia.
(continued)
Key Points
Question What is the antibiotic
coverage offered by empirical neonatal
sepsis treatment with aminopenicillin-
gentamicin, third-generation
cephalosporins (cefotaxime or
ceftriaxone), andmeropenem in Asian
countries?
Findings In this decision analytical
model based on a decision tree, 8376
isolates from 10 countries were used to
estimate coverage. Meropenem
generally had the highest coverage
(from 64.0% in India to 90.6% in
Cambodia) followed by aminopenicillin-
gentamicin (from 35.9% in Indonesia to
81.0% in Laos) and cefotaxime or
ceftriaxone (from 17.9% in Indonesia to
75.0% in Laos); in all countries except
Laos and Nepal, meropenem coverage
was higher than that of the other 2
regimens.
Meaning The findings suggest that
noncarbapenems may provide limited
empirical neonatal sepsis coverage in
many Asian countries.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE This study’s findings suggest that noncarbapenem antibiotic
regimensmay provide limited coverage for empirical treatment of neonatal sepsis in many Asian
countries. Alternative regimensmust be studied to limit carbapenem consumption.
JAMA Network Open. 2020;3(2):e1921124. doi:10.1001/jamanetworkopen.2019.21124
Introduction
Although overall maternal and child mortality have substantially declined worldwide since the early
2000s, neonatal mortality associated with bacterial infection has remained high, with nearly half a
million estimated annual deaths due to neonatal sepsis.1 Most of these deaths occur in low- and
middle-income countries (LMICs), includingmany thousands in Asia.2
In a recent prospective cohort study3 of more than 13 500 live births in India, the case-fatality
rate of culture-positive neonatal sepsis episodes was nearly 50%. Recent systematic reviews4-7
indicate a high level of bacterial resistance toWorld Health Organization (WHO)–recommended
empirical treatment regimens for serious neonatal and pediatric infections in LMICs, especially in
bloodstream isolates. Globally, antimicrobial resistance is estimated to be implicated in up to
one-third of neonatal sepsis deaths annually.8
Clinicians and guideline-setting bodies can be assisted in selecting optimal empirical antibiotic
regimens by knowing the coverage of alternative regimens.9 Regimen coverage refers to the
proportion of infection episodes that would be treated by the regimen at a stage when the causative
pathogen is not yet known, therefore incorporating the frequencies of different causative bacteria
and their resistance patterns. Several techniques are available to estimate coverage. One example is
theweighted-incidence syndromic combination antibiogram (WISCA),9-11 which estimates coverage
by accounting for the relative incidence of different bacteria and their resistance patterns for a
specific infection syndrome, in this case neonatal sepsis. Coverage can be estimated for both single-
drug and combination treatment regimens.
International guidelines provide recommendations for the empirical antibiotic treatment of
neonatal bacterial infections and should aim to provide adequate coverage in target settings,
especially LMICs.12 The objective of this decision analytical model study was, therefore, to evaluate
the coverage offered by 3 prespecified antibiotic regimens according toWISCAs and focusing on Asia,
a region with a high prevalence of bacterial resistance.
Methods
We estimated coverage using data on antimicrobial resistance that were used to createWISCAs for
each country with reported data,9 as identified by a systematic review of the literature. Because only
published data were used in the analysis, no formal ethical reviewwas required according to
guidance by the NHS Health Research Authority. This study follows the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) reporting guideline, because it is broadly applicable
to any decision-model based analyses (eAppendix in the Supplement).13
Regimens Selected for Coverage Estimation
The 3 regimens evaluated in this study were aminopenicillin-gentamicin (WHO-recommended first-
line treatment; alternatives, benzylpenicillin or cloxacillin plus gentamicin), third-generation
cephalosporins (WHO-recommended second-line treatment, assumed to be cefotaxime or
ceftriaxone, not ceftazidime), andmeropenem.12 The last regimen was evaluated because it has now
been reported to be themost commonly used empirical treatment in LMICs for neonatal sepsis.14
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Identification of Relevant Data for Parameter Estimation
A systematic search of the literature was conducted in Ovid MEDLINE and in Embase on January 23,
2019. Using both free-text andMeSH terms, publications on “sepsis” and “antibiotic resistance” and
(“neonates” or infants”) and “Asia” were identified (eAppendix in the Supplement). Given increasing
antimicrobial resistance, and to obtain contemporaneous estimates, we arbitrarily limited the search
to articles published from 2014 onward. No additional limits were applied. Studies were reviewed
against prespecified eligibility criteria, and data were extracted using a standardized prepiloted form
implemented in REDCap15 (eAppendix in the Supplement).
Extracted data for WISCA calculation included information on the total number of bacterial
isolates from relevant blood cultures, the number of isolates of specific bacterial species or genera,
the number of isolates tested for susceptibility to the antibiotics relevant for establishing coverage
offered by the prespecified regimens of interest, and the number of isolates found to be susceptible
to these antibiotics.We excluded bacteria known to frequently represent contamination rather than
true infection, most importantly coagulase-negative staphylococci.16 The exclusion of coagulase-
negative staphylococci is likely to result in the overestimation of coverage for β-lactam–based
regimens because of very high expected rates ofmethicillin resistance of 66% tomore than 90%.17,18
Estimation ofWISCAParameters
Tables containing the parameter values required for coverage estimation were created by country
and regimen. The relative incidence parameters were based only on bacteria reported as
contributing to neonatal sepsis in more than 50% of the eligible studies. This meant that estimated
coverage was based on themost important and frequent pathogens identified in blood cultures from
neonates in the target region. Including rare pathogens within theWISCAwould have aminimal
impact on the estimated coverage, and including those likely to be contaminants or unusual
pathogens (potentially observed as part of unidentified outbreaks) could introduce substantial bias.
For the bacteria identified in this way, their relative incidencewas based on the frequency reported
in the studies. Similarly, regimen susceptibility was derived directly from reported data with the
number of tested isolates representing the denominator. Details of the assumptions for determining
susceptibility of pathogens to each regimen are provided in the eAppendix in the Supplement.
Statistical Analysis
Regimen coverage was estimated using a previously described BayesianWISCA.9 This approach has
various advantages. It addresses the typical clinical approach of treating an infection syndrome, often
with incomplete knowledge about the frequency of causative bacteria and their susceptibilities. The
BayesianWISCA also explicitly deals with intrinsic resistance and handles imprecision attributed to a
small sample size or incomplete susceptibility testing data.
In brief, theWISCA gives the expected levels of therapeutic coverage for an antibiotic
regimen—in our case, regimens used to treat neonates with sepsis. TheWISCA can be represented as
a decision tree (eFigure 1 in the Supplement). Combining the probabilities along the regimen tree
branches generates coverage estimates from relative bacterial incidence and proportions of each
included pathogen susceptible to the antibiotic regimen. In essence, theWISCA is a weightedmean
of the susceptibilities of the bacteria, with the weights defined by their relative incidence.
The observed data on pathogen incidence and their susceptibility to the 3 regimens were
combined with an appropriate Bayesian prior distribution that corresponded to our prestudy beliefs
about these parameters.We had no strong prior belief about the relative incidence of the pathogens
or for the majority of what level of susceptibility there might be within a country, and a
noninformative prior was used in these cases. However, in some circumstances, specific pathogens
were expected to have intrinsic resistance to the regimen and, consequently, not to have
susceptibility regardless of reported susceptibility testing results.19,20 In these situations, an
informative prior was used to dominate the observed data. On the basis of European Committee for
Antimicrobial Susceptibility Testing (EUCAST) recommendations,19,20 enterococci, as well as
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Acinetobacter species and Pseudomonas species, were assumed to be intrinsically resistant to
recommended third-generation cephalosporins and therefore not susceptible to third-generation
cephalosporins.
The value of the pathogen incidence and pathogen regimen-susceptibility parameters were
defined as probability distributions to reflect the uncertainty in their respective values. The relative
incidence of pathogens wasmodeled using a Dirichlet distribution, and the susceptibility parameters
were defined as beta distributions; 95% credible intervals (95% CrIs) for the coverage estimates
were calculated using Monte Carlo simulations, based on 1000 runs (eAppendix in the Supplement).
All modeling was undertaken using Stata statistical software version 13.1 (StataCorp) and Excel
spreadsheet software version 2010 (Microsoft Corp). Data analysis was performed from April 2019
to July 2019.
Results
Description of Data Set
The literature review included data from 48 publications (eFigure 2 in the Supplement) representing
52 centers in 10 Asian countries (1 center in Cambodia, 5 in China, 33 in India, 1 in Indonesia, 1 in Laos,
1 in Malaysia, 6 in Nepal, 2 in Pakistan, 1 in Taiwan, and 1 in Vietnam). Of the 52 centers, 34 were
university or tertiary hospitals, 10 were nonteaching or district hospitals (9 in India and 1 in China),
and 8werematernity or pediatric hospitals (1 in Cambodia, 2 in China, 4 in Nepal, and 1 in Vietnam).
Ten articles were published in 2014, 13 in 2015, 10 in 2016, 8 in 2017, 6 in 2018, and 1 in 2019. For
32 of 48 publications, the observation period started in 2010 or later, with the earliest start date
being January 1, 1990 (eTable 1 in the Supplement). Five publications did not report calendar dates
for their observation period, but 4 of 5 indicated its duration. The median observation period was 2
years, with the shortest and longest periods being 2months and 12 years, respectively.
Most publications (33 of 48) reported on bloodstream isolates from neonates with clinical
community-acquired or nosocomial sepsis. Another 12 publications based reporting on
microbiologically defined bacteremia. Only 4 publications focused on either nosocomial or
community-acquired infections (2 each). Reporting of information on sample processing, including
species identification, antibiotic susceptibility testing methods, and interpretive guidelines, was
variable (eTable 2 in the Supplement).
Reported Bloodstream Isolates
Individual publications included between 15 and 2112 isolates, with a median of 98 isolates (eTable 3
in the Supplement). The following bacteria were most frequently reported as contributing to
neonatal sepsis or bacteremia: Escherichia coli (46 of 48 publications), Klebsiella species and
Staphylococcus aureus (45 of 48 publications each), Pseudomonas species (35 of 48 publications),
Acinetobacter species (32 of 48 publications), Enterobacter species (26 of 48 publications), and
Enterococcus species (25 of 48 publications). In addition, coagulase-negative staphylococci were
reported in 40 of 48 publications. All other bacteria, including Citrobacter species and Streptococcus
agalactiae, were reported in less than one-half of the publications. On the basis of the prespecified
criteria, E coli, Klebsiella species, S aureus, Pseudomonas species,Acinetobacter species, Enterobacter
species, and Enterococcus species were selected for antibiotic regimen coverage estimation.
Parameter Values: Isolates Reported and Susceptibility
In total, 11 467 isolates were reported, with the greatest number coming from India (6284), China
(2043), Pakistan (1875), and Nepal (640) (Table 1). Given the small number of reported isolates from
Taiwan (36) andMalaysia (29), antibiotic regimen coveragewas not estimated for these 2 countries.
Most reported isolates (8584 of 11 467 [74.9%]) were from university or tertiary hospitals, with
nonteaching or district hospitals contributing 11.5% (1319 of 11 467) andmaternity or pediatric
hospitals contributing another 13.6% (1564 of 11 467).
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In total, 8376 isolates from 10 countries were used to estimate coverage. The proportion of
reported isolates contributing to antibiotic regimen coverage estimation ranged from 91.9% (1723 of
1875) in Pakistan to 44.2% (905 of 2043) in China. Disregarding coagulase-negative staphylococci,
the proportion of reported bacterial isolates contributing to coverage estimation ranged from98.0%
(51 of 52) in Vietnam to 69.5% (905 of 1302) in China.
Availability of susceptibility testing information for aminopenicillin-gentamicin coverage ranged
from 68.8% (623 of 905) in China to 100% in Indonesia (Table 2). For third-generation
cephalosporins, this was available for 100% in Cambodia and Indonesia and 76.5% (39 of 51) in
Vietnam (Table 3). For meropenem, available susceptibility testing information ranged from 100%
in Indonesia to 60.3% (295 of 489) in Nepal (Table 4).
Coverage Estimates at Country Level
Coverage was consistently lowest for third-generation cephalosporin monotherapy, with some
variation across the individual countries, ranging from 56.6% (95% CrI, 52.2%-60.7%) in Nepal to
17.9% (95% CrI, 11.7%-24.7%) in Indonesia (Figure). Similarly, althoughmeropenem had the highest
estimated coverage in each country, the proportion of neonates for whom it would be effective
empirical treatment varied considerably, from 90.6% (95% CrI, 86.2%-94.4%) in Cambodia to
64.0% (95% CrI, 62.6%-65.4%) in India (Figure). Aminopenicillin-gentamicin offered the second
highest level of coverage within each country behindmeropenem. Nonetheless, there was again
considerable variability in country-level estimates, from 74.3% (95% CrI, 70.3%-78.2%) in Nepal to
35.9% (95% CrI, 27.7%-44.0%) in Indonesia (Figure).
Aminopenicillin-gentamicin coverage was higher than that offered by third-generation
cephalosporins in China (60.6% [95% CrI, 54.2%-67.5%] vs 44.2% [95% CrI, 40.9%-47.9%]), India
(45.1% [95% CrI, 43.7%-46.6%] vs 30.4% [95% CrI, 29.2%-31.6%]), Indonesia (35.9% [95% CrI,
27.7%-44.0%] vs 17.9% [95% CrI, 11.7%-24.7%]), and Nepal (74.3% [95% CrI, 70.3%-78.2%] vs
56.6% [95% CrI, 52.2%-60.7%]). There was greater uncertainty about whether the differences
observed for Cambodia (47.4% [95% CrI, 38.1%-56.6%] vs 32.6% [95% CrI, 25.8%-39.9%]), Laos
(81.0% [95% CrI, 71.1%-89.7%] vs 75.0% [95% CrI, 64.8%-84.1%]), Pakistan (42.2% [95% CrI,
39.1%-45.0%] vs 37.4% [95% CrI, 34.4%-40.3%]), and Vietnam (36.2% [95% CrI, 24.5%-49.0%] vs
21.5% [95% CrI, 12.0%-32.9%]) were due to chance variation.
Table 1. Relative Incidence Data
Pathogen
Isolates, No. (%)a
Cambodia
(n = 185)
China
(n = 2043)
India
(n = 6284)
Indonesia
(n = 225)
Laos
(n = 75)
Malaysia
(n = 29)
Nepal
(n = 640)
Pakistan
(n = 1875)
Taiwan
(n = 36)
Vietnam
(n = 75)
Total
(N = 11 467)
Contributing to WISCA
Escherichia coli 25 (16) 300 (33) 671 (14) 0 8 (13) 6 (33) 50 (10) 976 (57) 11 (92) 2 (4) 2049 (24)
Klebsiella species 60 (39) 264 (29) 1065 (22) 49 (40) 9 (14) 1 (6) 45 (9) 159 (9) 1 (8) 18 (35) 1671 (20)
Enterobacter species 18 (11) 58 (6) 167 (3) 20 (17) 4 (6) 0 30 (6) 0 0 6 (12) 303 (4)
Acinetobacter species 16 (10) 27 (3) 992 (21) 21 (17) 2 (3) 0 63 (13) 0 0 17 (33) 1138 (14)
Pseudomonas species 6 (4) 53 (6) 430 (9) 31 (26) 1 (2) 1 (6) 25 (5) 199 (12) 0 4 (8) 750 (9)
Staphylococcus aureus 33 (21) 112 (12) 1235 (26) 0 37 (58) 10 (55) 261 (53) 388 (23) 0 4 (8) 2080 (25)
Enterococcus species 0 91 (10) 275 (6) 0 3 (5) 0 15 (3) 1 (<1) 0 0 385 (5)
Total reported during observation period
Total contributing
to WISCA
158 (85) 905 (44) 4835 (77) 121 (54) 64 (85) 18 (62) 489 (76) 1723 (92) 12 (33) 51 (68) 8376 (73)
Other
(not contributing
to WISCA)
27 (15) 1138 (56) 1449 (23) 104 (46) 11 (15) 11 (38) 151 (24) 152 (8) 24 (67) 24 (32) 3091 (27)
Coagulase-negative
staphylococci
(not contributing
to WISCA)
0 741 (36) 980 (16) 63 (28) 0 0 137 (21) 28 (1) 0 23 (31) 1972 (17)
Abbreviation: WISCA, weighted-incidence syndromic combination antibiogram.
a Percentages may not add to 100% because of rounding.
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Meropenem coverage was higher than aminopenicillin-gentamicin coverage in Cambodia
(90.6% [95% CrI, 86.2%-94.4%] vs 47.4% [95% CrI, 38.1%-56.6%]), China (76.5% [95% CrI, 71.8%-
80.9%] vs 60.6% [95% CrI, 54.2%-67.5%]), India (64.0% [95% CrI, 62.6%-65.4%] vs 45.1% [95%
CrI, 43.7%-46.6%]), Indonesia (88.8% [95% CrI, 83.2%-93.6%] vs 35.9% [95% CrI, 27.7%-44.0%]),
Pakistan (88.1% [95% CrI, 85.6%-90.3%] vs 42.2% [95% CrI, 39.1%-45.0%]), and Vietnam (84.1%
[95% CrI, 73.2%-92.6%] vs 36.2% [95% CrI, 24.5%-49.0%]) on the basis of nonoverlapping 95%
CrIs. The largest percentage differences in coverage were observed in Indonesia (52.9%), Pakistan
(45.9%), and Cambodia (43.2%); the smallest was in China (15.9%). For meropenem and third-
generation cephalosporins, the percentage difference was largest for Indonesia (70.9%), Vietnam
(62.6%), and Cambodia (58.0%). Of note, for Laos and Nepal, imprecision around estimated
meropenem coverage, which was comparable with that of aminopenicillin-gentamicin with
overlapping 95% CrIs, was largely because of low proportions of isolates (62.5% [40 of 64] for Laos
and 60.3% [295 of 489] for Nepal) contributing to themeropenem susceptibility parameter.
Discussion
We estimated the coverage offered by 3 antibiotic regimens—aminopenicillin-gentamicin (WHO-
recommended first-line regimen), third-generation cephalosporins (WHO-recommended second-
line regimen), and meropenem—in Asian countries for the empirical treatment of neonatal sepsis
caused by 7 specified bacteria. The coverage estimates were based on a systematic review of recent
studies reporting on the relative incidence of common bacteria and their resistance.
In general, coverage estimates supported the identification of better-performing or worse-
performing regimens for most countries. Coverage offered by aminopenicillin-gentamicin (WHO-
recommended first-line regimen) was less than 50% for Cambodia, India, Indonesia, Pakistan, and
Vietnam and less than 75% for China and Nepal. Even lower coverage was offered by the
WHO-recommended second-line third-generation cephalosporinmonotherapy regimen: below 50%
Figure. Coverage Estimates for 8 Asian Countries
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Point estimates are shownwith 95% credible intervals, as denoted by error bars.
Nonoverlapping 95% credible intervals indicate likely within-country differences in
regimen coverage. Countries are shown together with the overall number of isolates
used for estimating coverage.
a The highest coverage offered bymeropenemwas in Cambodia (90.6%), China
(76.5%), India (64.0%), Indonesia (88.8%), Pakistan (88.1%), and Vietnam (84.1%).
b The highest coverage offered by aminopenicillin-gentamicin combination was in Laos
(81.0%) and Nepal (74.3%).
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in all represented countries except Laos (75.0%) and Nepal (56.6%). Meropenem coverage was
generally highest and was greater than 80% in Cambodia, Indonesia, Pakistan, and Vietnam, but
lower than 80% in China, Laos, and Nepal and as low as 64.0% in India. Considerable between-
country differences were observed for all 3 regimens, even for countries bordering each other, such
as Cambodia, Laos, Thailand, and Vietnam.
Coverage estimates are clinically highly relevant for the development of local and national
empirical treatment guidelines, incorporating both the relative incidence of bacteria and their
susceptibility.9 This concept has not, to our knowledge, been previously applied to neonatal sepsis in
LMICs. Instead, reports have focused on susceptibility for individual pathogen-drug combinations,
an approach that does not directly incorporate the spectrum of causative bacteria.4,6,7
One important question is whether global setting-independent recommendations for empirical
neonatal sepsis treatment can be supported in an era of changing and highly variable epidemiology.
In some settings, difficult-to-treat pathogens and multidrug-resistant isolates now contribute
considerably to neonatal sepsis.3 Stratified guidancemoving between recommended regimens
according to microbiology and coverage by patient-level factors (eg, presence of certain underlying
conditions or timing of sepsis onset) or setting, may be a solution. One challenge will be the lack of
defined coverage thresholds to move between regimens.21 Given sufficiently large data sets,
coverage estimates could help inform such shifting by supporting inferences about true differences
between regimens.
Limitations
This study has some limitations. Our coverage estimates were based on data from predominantly
university or teaching hospitals. Infants with complex medical issues and those at higher risk of
nosocomial bloodstream infections may, therefore, be overrepresented. At the same time,
microbiology data from infants managed in district hospitals are lacking precluding confirmation that
presented coverage estimates are applicable to them as well. Clinicians applyingWHO
recommendations to infants with nosocomial infection or thosemanaged in tertiary hospitals would,
on the basis of our observations, need to consider alternatives for this population.
We chose to estimate coverage according to the pathogens frequently reported across included
studies, which are likely to be associated with severe neonatal sepsis and the so-called ESKAPE
organisms (ie, Enterococcus faecium, S aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and
Pseudomonas aeruginosa), which are known to be problematic in terms of emerging antimicrobial
resistance.22 Inclusion of other pathogens would be expected to have a variable influence on the
expected coverage of considered antibiotics, leading to either higher or lower estimates. This may be
particularly important in individual hospitals with ongoing outbreaks where a single bacterial strain
is dominant. In such situations, regional coverage estimates may not be applicable.
Coverage estimation requires a number of assumptions to bemade when calculating the
susceptibility parameters, such as the incorporation of intrinsic resistance, extrapolations from
susceptibility testing for 1 representative of an antibiotic class to other members of this class, and the
interpretation of multiple testing for 1 antibiotic class. We based our calculations of regimen
susceptibility on EUCAST algorithms and, whenever possible, used susceptibility testing information
for the specific drug of interest.19 Importantly, however, all included studies used versions of Clinical
and Laboratory Standards Institute interpretive criteria,23 which may diverge from EUCAST in terms
of both break points and assumptions about intrinsic resistance. Debate about themerits and
challenges of switching from Clinical and Laboratory Standards Institute to EUCAST and about the
implications of such a transition for interpretation of routine data in the context of surveillance
is ongoing.23,24
To support coverage estimation, it is important that themicrobiological data used are collected
in equivalent ways. However, the data used for this analysis may have been subject to various
random or systematic errors that could bias the coverage estimates. Possible sources of error include
duplicate isolates, contaminants, nonstandardized susceptibility testing, combining data from
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different patient populations (children and adults), and reflex susceptibility testing based on
resistance identified in a first-line testing panel.25 These requirements have important implications
for global surveillance initiatives, such as the Global Antimicrobial Resistance Surveillance System,26
if data collected are to be used at the interface between surveillance and clinical practice.
Conclusions
Recently, machine learning approaches andmore elaborate multivariable Bayesian models using
clinical and demographic information combined with microbiological data have been proposed as
optimizing the selection of empirical antibiotic treatment for sepsis.27,28 Although thesemodels may
help in selecting patient-adapted regimens, the approach used in our study only requires estimates
of pathogen incidence and susceptibility and could already substantially improve clinical decision-
making based on routine microbiological data alone, provided that the data used to produce these
estimates are of sufficient quality. Our analysis indicates that the recommendation for third-
generation cephalosporin monotherapy as a second-line regimenmay no longer be valid for many
infants receiving treatment for neonatal sepsis in several Asian countries. Our findings could explain
the high reported empirical meropenem use in this population in Asia.14,29 Evaluation of potential
alternatives will be essential to reducing consumption of last-resort antibiotics for the empirical
treatment of neonatal sepsis in settings with a high prevalence of antimicrobial resistance.
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